Release Date: January 30, 2026
Expiration Date: January 30, 2027
Activity Overview
This Expert Illustrations and Commentaries is a video-based program in which expert faculty discuss the the mechanism of action of and recent clinical data on bispecific antibodies and bispecific T-cell engager agents (BiTEs) in patients with thoracic tumors. Their discussion is supplemented by video animations designed to help learners better understand the role of new and emerging agents. This unique format helps clinicians identify best practices in the diagnosis and management of thoracic tumors, and incorporate new clinical trial data in their practice to improve outcomes for their patients.
Target Audience
This educational activity is directed toward medical oncologists, advanced practice providers, oncology nurses, and other clinicians interested in the management of patients with solid tumors.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the structure and mechanisms of emerging PD-1/CTLA-4 bispecific antibodies being evaluated for the treatment of solid tumors
- Describe the mechanistic differences between bispecifics utilizing dual checkpoint blockade and bispecific T-cell engagers, along with potential implications for efficacy and safety
- Integrate the latest data for bispecific therapies into personalized treatment plans for patients with solid tumors
John V. Heymach, MD, PhD
Ruth Legett Jones Distinguished Chair
Chair of Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston,
TX
Disclosures: Advisor/Consultant/Speaker/Honoraria Recipient: 23andMe, AstraZeneca, Bayer, BioNTech AG, BI, BMS, Eli Lilly & Co, Limited, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Mirati Therapeutics, ModeX, Ottimo Pharma, Pfizer, Regeneron Pharmaceuticals, Remunity Therapeutics, Synthekine, Takeda Pharmaceuticals; Grant/Research Funding: AstraZeneca, BMS, BI, Dizal, Taiho, Takeda
Anne S. Tsao, MD, MBA, FASCO, FACHE
Vice President, Academic Affairs
Chief Academic Office
Professor, Thoracic/Head and Neck Medical Oncology
Director, Mesothelioma Program
The University of Texas MD Anderson Cancer Center
Houston, TX
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
